Literature DB >> 24232504

Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study.

Gian Luca Erre, Luisanna Bosincu, Rossana Faedda, Patrizia Fenu, Antonio Masala, Marcella Sanna, Loredana Taras, Maria Giovanna Longu, Marco Piras, Giovanni Soro, Andrea Ercole Satta, Giuseppe Passiu.   

Abstract

Data about clinical-laboratory features and outcome of antiphospholipid syndrome nephropathy (APSN) in the course of lupus nephritis (LN) are scarce. To determine prevalence, clinical correlations and outcome of APSN in patients with LN, retrospective analysis of renal specimens and review of medical records from 48 LN patients were performed. APSN was found in 12/48 (25 %) of LN. Positivity for lupus anticoagulant (LAC) and double antiphospholipids positivity [LAC plus anticardiolipin (aCL)] were significantly more frequent in APSN-LN (p = 0.02 and p = 0.01, respectively) than in LN, while single aCL positivity was not. Overt antiphospholipid syndrome appeared more frequent in patients with APSN-LN (p = 0.05). There were no statistically significant differences between APSN-LN and LN in the proportion of each World Health Organization class of LN (with the exception of a trend toward fewer Class III LN in APS-LN) and in the systemic lupus erythematosus (SLE) disease duration and severity. At the time of renal biopsy, patients with APSN-LN had median serum creatinine levels significantly higher than patients with LN [1.45 (0.6-6.6) vs. 1.00 (0.7-3.0), p = 0.02]. Double antiphospholipid positivity was the only variable significantly associated with APSN-LN at multivariate regression analysis (OR 8, 95 % CI 1.7-37, p = 0,008). APSN-LN and LN did not differ significantly as regards the rate of complete (25 vs. 19.4 %, p = 0.72) and partial treatment response (25 vs. 29 %, p = 0.82) at 6 months and the progression to end-stage renal disease after a median follow-up of 8.1 ± 3.6 years (16.6 vs. 13.8 %, p = 0.82). APSN was demonstrated in a quart of LN, appeared to be independent from underlying LN class and SLE severity, and did not seem to confer a worse prognosis to LN. The findings of higher creatinine and more interstitial fibrosis in APSN should be confirmed in future prospective larger studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24232504     DOI: 10.1007/s00296-013-2900-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  34 in total

1.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

2.  Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions.

Authors:  R Cervera; M G Tektonidou; G Espinosa; A R Cabral; E B González; D Erkan; S Vadya; H E Adrogué; M Solomon; G Zandman-Goddard; Y Shoenfeld
Journal:  Lupus       Date:  2011-02       Impact factor: 2.911

3.  Evaluation of clinical outcomes and renal vascular pathology among patients with lupus.

Authors:  Claire Barber; Andrew Herzenberg; Ellie Aghdassi; Jiandong Su; Wendy Lou; Gan Qian; Jonathan Yip; Samih H Nasr; David Thomas; James W Scholey; Joan Wither; Murray Urowitz; Dafna Gladman; Heather Reich; Paul R Fortin
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 8.237

4.  Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus.

Authors:  R Silvariño; F Sant; G Espinosa; G Pons-Estel; M Solé; R Cervera; P Arrizabalaga
Journal:  Lupus       Date:  2011-04-12       Impact factor: 2.911

5.  Membranous nephropathy in primary antiphospholipid syndrome: description of a case and induction of renal injury in SCID mice.

Authors:  Y Levy; L Ziporen; B Gilburd; J George; S Polak-Charcon; H Amital; J Cledes; P Youinou; Y Shoenfeld
Journal:  Hum Antibodies Hybridomas       Date:  1996

6.  Clinical significance of antiphospholipid syndrome nephropathy (APSN) in patients with systemic lupus erythematosus (SLE).

Authors:  Juan M Miranda; Luis J Jara; Concepción Calleja; Miguel A Saavedra; Reyna M Bustamante; Ulises Angeles
Journal:  Reumatol Clin       Date:  2009-05-06

Review 7.  Antiphospholipid syndrome and the kidneys.

Authors:  Imad Uthman; Munther Khamashta
Journal:  Semin Arthritis Rheum       Date:  2006-06       Impact factor: 5.532

8.  Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone.

Authors:  K E Moss; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-08       Impact factor: 7.580

9.  Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure.

Authors:  P Kincaid-Smith; K F Fairley; M Kloss
Journal:  Q J Med       Date:  1988-10

10.  Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants.

Authors:  H I Glueck; K S Kant; M A Weiss; V E Pollak; M A Miller; M Coots
Journal:  Arch Intern Med       Date:  1985-08
View more
  8 in total

Review 1.  The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions.

Authors:  Suzanne Wilhelmus; Charles E Alpers; H Terence Cook; Franco Ferrario; Agnes B Fogo; Mark Haas; Kensuke Joh; Laure-Hélène Noël; Surya V Seshan; Jan A Bruijn; Ingeborg M Bajema
Journal:  J Am Soc Nephrol       Date:  2015-07-07       Impact factor: 10.121

Review 2.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

Review 3.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

Review 4.  Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.

Authors:  Alberto Floris; Matteo Piga; Arduino Aleksander Mangoni; Alessandra Bortoluzzi; Gian Luca Erre; Alberto Cauli
Journal:  Mediators Inflamm       Date:  2018-02-18       Impact factor: 4.711

Review 5.  Neurology of rheumatologic disorders.

Authors:  Amre Nouh; Olimpia Carbunar; Sean Ruland
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 6.030

6.  Lupus Nephritis with Coexistent Antiphospholipid Antibodies Associated Nephropathy: A Case Report and Literature Review.

Authors:  K Talari; U Anandh; A Patrick
Journal:  Indian J Nephrol       Date:  2018 Mar-Apr

7.  Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome.

Authors:  Hironari Hanaoka; Harunobu Iida; Tomofumi Kiyokawa; Yukiko Takakuwa; Takahiro Okazaki; Hidehiro Yamada; Shoichi Ozaki; Kimito Kawahata
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

Review 8.  Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

Authors:  Myrto Kostopoulou; Antonis Fanouriakis; Kim Cheema; John Boletis; George Bertsias; David Jayne; Dimitrios T Boumpas
Journal:  RMD Open       Date:  2020-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.